IL-6: from arthritis to CAR-T-cell therapy and COVID-19

Tadamitsu Kishimoto

Laboratory of Immune Regulation, WPI Immunology Frontier Research Center, Osaka University, 565-0871 Suita City, Osaka, Japan

Correspondence to: T. Kishimoto; E-mail: kishimoto@ifrec.osaka-u.ac.jp

Received 12 February 2021, editorial decision 9 March 2021, accepted 12 March 2021

Abstract

Blockade of IL-6 function by an anti-IL-6 receptor (IL-6R) antibody (tocilizumab, trade name Actemra) has been shown to be effective for the treatment of chronic autoimmune inflammatory diseases including rheumatoid arthritis. Interestingly, treatment with tocilizumab has also been found to alleviate the cytokine storm induced by chimeric antigen receptor (CAR)-T-cell therapy. Patients with serious cases of coronavirus disease 2019 (COVID-19) exhibit cytokine release syndrome (CRS), which suggested that tocilizumab might be an effective therapeutic for serious cases of COVID-19. In the first part of this short review, the therapeutic effect of tocilizumab for the disease induced by IL-6 overproduction is described. CRS induced by CAR-T-cell therapy and COVID-19 is then discussed.

Keywords: cytokine release syndrome, cytokine storm, tocilizumab

Introduction: pleiotropic functions and the unique receptor system of IL-6

IL-6 was originally discovered as a B-cell differentiation factor that induces B cells to become antibody-producing cells (1). After the cDNA encoding this molecule was first isolated in 1986 (2), subsequent studies with recombinant IL-6 and anti-IL-6 antibodies revealed that this molecule has a wide range of biological functions (3). As shown in Fig. 1, IL-6 acts not only on the immune system but also in nearly all tissues and cells, including liver, bone, muscle and hematopoietic cells and neuronal tissue. In liver cells, IL-6 acts as a hepatocyte-stimulating factor, induces various acute-phase proteins—such as C-reactive protein (CRP), fibrinogen and hepcidin—and inhibits albumin production.

Although the originally identified 80-kDa IL-6 receptor (IL-6R) (4) is expressed on only immune-related tissues and cells, IL-6 is able to have a wide variety of biological functions throughout the body because of the unique IL-6R system (Fig. 2). The IL-6R system is composed of two polypeptide chains. The 80-kDa IL-6R has a short intra-cytoplasmic portion that is unable to transduce signals into cells. A separate 130-kDa receptor component called gp130 (5) is expressed by all tissues and cells. When IL-6 binds to the 80-kDa IL-6R, the resulting IL-6–receptor complex dimerizes with gp130, after which signals can be transduced through gp130. Additionally, the proteinase ADAM metalloprotease 17 (ADAM17) cleaves membrane-bound IL-6R into soluble IL-6R, which can form a soluble complex of IL-6 and IL-6R. This soluble complex can also bind with gp130 to form a hexamer complex (composed of dimers of IL-6, IL-6R and gp130) that can transduce IL-6 signals.

Because of its unique receptor system, IL-6 is a pleiotropic cytokine. As described below, elevated levels of both IL-6 and soluble IL-6R are found in the serum of patients with various autoimmune inflammatory diseases or cytokine release syndromes (CRS). Furthermore, gp130 functions as a signal transducer not only for IL-6 but also for several other cytokines, such as leukemia inhibitory factor, oncostatin M, ciliary neurotrophic factor, IL-11, IL-27, IL-31 and cardiotoxhin. Consequently, all these cytokines show similar redundant and pleiotropic functions (6).

Antibody-based therapy of autoimmune inflammatory diseases

Several clinical observations have suggested that IL-6 overproduction induces various inflammatory phenomena. For example, in a patient with cardiac myxoma (7) who showed a high fever and elevated CRP levels, all their inflammatory symptoms disappeared after the myxoma was surgically removed, and the myxoma tissue showed a high IL-6 titer. Additionally, in a case of Castleman’s disease (8) where the patient exhibited high fever and anemia with an elevated CRP level and swelling of multiple lymph nodes, a biopsy of the affected lymph nodes revealed a high IL-6 titer in B cells within the germinal centers. Since these initial observations, IL-6 overproduction has been described in various autoimmune inflammatory diseases (Table 1).

An antibody directed against the 80-kDa IL-6R was prepared to treat these chronic inflammatory diseases. The
IL-6 and cytokine storm

Humanized anti-IL-6R antibody is called tocilizumab. As shown in Fig. 2, tocilizumab can block the binding of IL-6 with IL-6R as well as interfere with the formation of complexes of IL-6 with soluble IL-6R and inhibit gp130 dimerization. This signaling system is called IL-6 trans-signaling (3), and tocilizumab almost completely blocks IL-6 signals by these two pathways (Fig. 2). The clinical effect of tocilizumab is dramatic. It has been successfully used to treat patients with...
Castleman's disease, juvenile idiopathic arthritis (9), rheumatoid arthritis (10) and giant cell arteritis (11). Currently, over 1 million patients in more than 100 countries are treated with this antibody.

One regulatory mechanism of IL-6 production occurs at the mRNA level. Two molecules, endonucleases Regnase-1 (12) and Arid5A (13), act at the stem-loop of the 3′-untranslated region of IL-6 mRNA. Regnase-1 is involved in the degradation of mRNA, and it down-regulates IL-6 production. Arid5A binds to the same portion of the IL-6 mRNA, where it competes with Regnase-1 to protect the mRNA from degradation. Under normal conditions, Arid5A is present mainly in nuclei, but when inflammation occurs, it moves to the cytoplasm and stabilizes IL-6 mRNA, resulting in the overproduction of IL-6.

**CRS by chimeric antigen receptor T-cell therapy**

B precursor-acute lymphoblastic leukemia (B-ALL) is one of the most common childhood malignancies. The recently reported strategy of using chimeric antigen receptor (CAR)-modified T cells directed against the B-cell antigen CD19 (cluster differentiation 19) can effectively treat refractory B-ALL in children (14). CAR binding with CD19 B-ALL results in T-cell activation, antigen-mediated cell killing, and T-cell proliferation.

The robust expansion and sustained proliferation of the modified CAR-T-cell population can eradicate leukemic cells and appears to sustain remission in many patients. However, this robust T-cell proliferation also activates macrophages to produce inflammatory cytokines, particularly IL-6, which causes a unique, significant side effect of CAR-T-cell therapy, CRS. However, tocilizumab administration was found to effectively treat the CAR-T-cell-induced CRS, which likely saved CAR-T therapy. In the initial case for which the use of tocilizumab was tested, the patient’s high fever went down, low blood pressure went up, and serum IL-6 and CRP levels returned to normal only a couple of hours after tocilizumab administration (15).

As shown in Fig. 3, tocilizumab blocks the function of large amounts of IL-6 secreted from T-cell-stimulated macrophages and prevents CRS. Importantly, although steroid hormones such as dexamethasone can also prevent CRS, they block the antitumor effect of CAR-T cells. CAR-T-cell therapy has now been approved for clinical use in combination with tocilizumab for preventing CRS (15).

**CRS induced by systemic inflammatory responses to infection**

Excessive immune responses to bacterial or viral infections or tissue injury induce the overproduction of various cytokines, including IL-6, IL-10, IFN-γ, monocyte chemotactic protein-1 (MCP-1), tumor necrosis factor (TNF)-α, IL-2 and IL-8. Elevated levels of these cytokines are associated with the clinical manifestation of CRS. As shown in Fig. 4, patients with sepsis, acute respiratory distress syndrome (ARDS) or burns showed strikingly high serum levels of the cytokines IL-6, IL-8, MCP-1 and IL-10, while the levels of TNF-α, IL-1β, IL-12p40, IFN-α, IFN-γ, IL-17 and IL-4 were not significantly different from those in the healthy controls. The clinical severity of systemic inflammation is associated with vascular endothelial injuries and coagulopathy owing to the induction of vascular leakage and tissue hypoxia, which results in hypotension and multiple organ failure.

Plasminogen activator inhibitor-1 (PAI-1) levels are elevated in cases of systemic inflammation, especially sepsis-induced

---

**Fig. 3.** Schematic diagram of anti-IL-6R antibody treatment in the CAR-T-cell-induced cytokine storm. The anti-IL-6R antibody tocilizumab ameliorates CRS without impairing the cytotoxic effect of CAR-T cells.
intravascular coagulation (16), suggesting that the PAI-1 concentration is a predictor of CRS disease progression (Fig. 4). Importantly, serum IL-6 levels were positively correlated with elevated IL-8, IL-10, MCP-1 and PAI-1 levels in cases of sepsis, ARDS and burns. The elevated PAI-1 levels in CRS from various causes, such as sepsis, ARDS and burns, indicate that vascular endothelial cells play a major role in CRS. Indeed, in vitro stimulation of vascular endothelial cells with IL-6 and soluble IL-6R was found to induce increases in the levels of PAI-1, IL-6 and several other cytokines. Because vascular endothelial cells do not express IL-6R, a complex of IL-6 and soluble IL-6R stimulates the gp130 expressed by endothelial cells via IL-6 trans-signaling. This mechanism can explain the inhibitory effect of tocilizumab on vascular endothelial cells. Thus, tocilizumab blocks the production of IL-6 and several other cytokines, as well as that of PAI-1, by the mechanism of IL-6 trans-signaling. Our in vivo and in vitro studies showed that over-reactive endothelial cells are a critical factor in acute and systemic inflammation and multiple organ disorders.

Recently, coronavirus disease 2019 (COVID-19), caused by infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), was found to be associated with a broad spectrum of clinical features, such as interstitial pneumonia. Patients with COVID-19 develop ARDS and thrombosis, leading to severe vasculopathy. Notably, a critical feature of COVID-19 is the vascular changes associated with disease severity. For cases reported in Wuhan, IL-6 was one of the pivotal cytokines associated with lung damage progression during the COVID-19-induced cytokine storm (17). This observation suggested that an inhibition of IL-6 signaling could be effective for treating COVID-19-related pneumonia as well as CRS. The first trial of tocilizumab in severe COVID-19 patients, which occurred in Wuhan, indicated that tocilizumab has potential as an effective treatment; it improved the clinical symptoms, computed tomography opacity changes, and CRP concentrations of the treated patients (17).

Our retrospective data also indicate that patients with severe COVID-19 display a mild elevation in their levels of IL-6 and several other cytokines, along with a striking elevation of PAI-1 levels similar to those seen in patients with bacterial sepsis or ARDS (Fig. 4). Notably, tocilizumab treatment decreased the levels of both IL-6 and PAI-1 and also improved some clinical pneumonia symptoms in patients with severe COVID-19 (16). These data indicate that IL-6 signaling in the vascular endothelium plays pivotal roles in coagulation activation and thrombosis during the cytokine storm observed in patients with COVID-19.

Numerous clinical trials of tocilizumab as a COVID-19 treatment have now been conducted, but their results are inconsistent. In patients with moderate cases of COVID-19, no support was found for beneficial effects of tocilizumab treatment (18). For patients who were critically ill with COVID-19, the EMPACTA trial reported that tocilizumab treatment was associated with a reduction in the requirement for mechanical ventilation but did not improve the overall mortality.
(19). However, the REMAP-CAP trials in the UK, which assessed the effectiveness of a blockade of IL-6R signaling via tocilizumab or another anti-IL-6R antibody, sarilumab, found that both antibodies improved survival in patients with severe COVID-19 (20). These results suggest the beneficial efficacy of IL-6R antagonists in patients with COVID-19.

As mentioned, a complex of IL-6 and IL-6R transduces signals into the inside of cells through gp130. Dimerization of gp130 activates JAK–STAT3 signaling pathways. As expected, blockade of JAK–STAT3 signaling pathway by the anti-JAK kinase, baricitinib, shows beneficial effects together with remdesivir in hospitalized patients (21).

Compared with the CRS associated with CAR-T-cell therapy and other causes, the elevated serum IL-6 levels in patients with COVID-19 are 100-fold lower, but the PAI-1 levels are comparable. Thus, although the beneficial effect of tocilizumab for treating COVID-19 remains controversial, the treatment appears to be effective for vascular damage. The network of signal transduction between IL-6 and PAI-1 remains an interesting question to be addressed in future work.

Conclusions

As described here, IL-6 not only exhibits a wide variety of biological activities but also is involved in chronic autoimmun inflammation and can induce the acute shock condition known as a cytokine storm. A blockade of IL-6 signals produces significant clinical benefits for both autoimmune diseases and CRS. In this respect, the blockade of IL-6 signals with a steroid hormone has similar effects, as demonstrated by the clinical benefit of dexamethasone in the treatment of severe COVID-19. However, unlike treatment with steroid hormones, IL-6 signal inhibition does not globally suppress immune function. At present, how IL-6 can induce both acute and chronic inflammation remains incompletely understood. It is also unknown how IL-6 production is regulated, which is important because constitutive IL-6 production occurs in various diseases. This review conveys the contents of my lecture given for the Japanese Society of Immunology in 2020.

Funding

This work was supported by the Kishimoto Foundation.

Acknowledgements

I thank Dr S. Kang for assistance in preparing the manuscript and M. Okawa for providing secretarial help. I also thank Katie Oakley, PhD, from Edanz Group (https://en-author-services.edanz.com/ac), for editing a draft of this manuscript.

Conflicts of interest statement: T.K. holds the patent for Actemra.

References

1 Kishimoto, T. and Ishizaka, K. 1973. Regulation of antibody response in vitro. VII. Enhancing soluble factors for IgG and IgE antibody response. J. Immunol. 111:1194.

2 Hirano, T., Yasukawa, K., Harada, H. et al. 1986. Complementary DNA for a novel human interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulin. Nature 324:73.

3 Kang, S., Tanaka, T., Narazaki, M. and Kishimoto, T. 2019. Targeting interleukin-6 signaling in clinic. Immunity 50:1007.

4 Yamasaki, K., Taga, T., Hirata, Y. et al. 1988. Cloning and expression of the human interleukin-6 (BSF-2/IFN beta 2) receptor. Science 241:825.

5 Hibi, M., Murakami, M., Salti, M., Hirano, T., Taga, T. and Kishimoto, T. 1990. Molecular cloning and expression of an IL-6 signal transducer, gp130. Cell 63:1149.

6 Kang, S., Narazaki, M., Metwally, H. and Kishimoto, T. 2020. Historical overview of the interleukin-6 family cytokine. J. Exp. Med. 217:e20190347.

7 Hirano, T., Taga, T., Yasukawa, K. et al. 1987. Human B-cell differentiation factor defined by an anti-peptide antibody and its possible role in autoantibody production. Proc. Natl Acad. Sci. USA 84:228.

8 Yoshizaki, K., Matsuda, T., Nishimoto, N. et al. 1989. Pathogenic significance of interleukin-6 (IL-6/BSF-2) in Castleman’s disease. Blood 74:1360.

9 Yokota, S., Imagawa, T., Mori, M. et al. 2008. Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial. Lancet 371:998.

10 Nakahara, H., Song, J., Sugimoto, M. et al. 2003. Anti-interleukin-6 receptor antibody therapy reduces vascular endothelial growth factor production in rheumatoid arthritis. Arthritis Rheum. 48:1521.

11 Stone, J. H., Tuckwell, K., Dimonaco, S. et al. 2017. Trial of tocilizumab in giant-cell arteritis. N. Engl. J. Med. 377:317.

12 Matsushita, K., Takeuchi, O., Standley, D. M. et al. 2009. Zc3h12a is an RNAse essential for controlling immune responses by regulating mRNA decay. Nature 458:1185.

13 Masuda, K., Ripley, B., Nishimura, R. et al. 2013. Arid3a controls IL-6 mRNA stability, which contributes to elevation of IL-6 level in vivo. Proc. Natl Acad. Sci. USA 110:9409.

14 Porter, D. L., Hwang, W. T., Frey, N. V. et al. 2015. Chimeric antigen receptor T cells persist and induce sustained remissions of leukemic T cells for acute lymphoid leukemia. Sci. Transl. Med. 7:303ra139.

15 Grupp, S. A., Kalos, M., Barrett, D. et al. 2013. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N. Engl. J. Med. 368:1509.

16 Kang, S., Tanaka, T., Inoue, H. et al. 2020. IL-6 trans-signaling induces plasminogen activator inhibitor-1 from vascular endothelial cells in cytokine release syndrome. Proc Natl Acad Sci USA 117:22351.

17 Xu, X., Han, M., Li, T. et al. 2020. Effective treatment of severe COVID-19 patients with tocilizumab. Proc. Natl Acad. Sci. USA 117:10970.

18 Stone, J. H., Frigault, M. J., Serling-Boyd, N. J. et al.; BACC Bay Tocilizumab Trial Investigators. 2020. Efficacy of tocilizumab in patients hospitalized with COVID-19. N. Engl. J. Med. 383:2333.

19 Salama, C., Han, J., Yau, L. et al. 2021. Tocilizumab in patients hospitalized with COVID-19 pneumonia. N. Engl. J. Med. 384:20.

20 The REMAP-CAP Investigators; Gordon, A. C., Mouncey, P. R., Al-Beidh, F. et al. 2021. Interleukin-6 receptor antagonists in critically ill patients with Covid-19—preliminary report. medRxiv, doi: 10.1101/2021.01.07.21249390, 9 January, preprint: not peer reviewed.

21 Stebbing, J., Sanchez Nieves, G., Falcone, M. et al. 2021. JAK inhibition reduces SARS-CoV-2 liver infectivity and modulates inflammatory responses to reduce morbidity and mortality. Sci. Adv. 7:eabe4724.